欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子抑制剂 > CellCycle/Checkpoint > SAR-020106

浏览历史

S87999

SAR-020106

源叶(MedMol) 98%
  • 英文名:
  • (R)-5-((8-chloroisoquinolin-3-yl)amino)-3-((1-(dimethylamino)propan-2-yl)oxy)pyrazine-2-carbonitrile
  • 别名:
  • SAR020106; SAR020106; SAR 020106; SAR20106; SAR20106; SAR 20106.
  • CAS号:
  • 1184843-57-9
  • 分子式:
  • C19H19N6OCl
  • 分子量:
  • 382.84676
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
源叶(MedMol) S87999-5mg 98% ¥700.00元 4 - - - EA 加入购物车
源叶(MedMol) S87999-10mg 98% ¥1200.00元 4 - - - EA 加入购物车
源叶(MedMol) S87999-25mg 98% ¥2200.00元 5 - - - EA 加入购物车
源叶(MedMol) S87999-100mg 98% ¥6600.00元 预计交期:2-3天 - - - EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述: SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents
  • 靶点: Chk1:13.3 nM (IC50);Chk
  • 体外研究:
    SAR-020106 (0.1-1 μM; 23 hours) abrogates an Etoposide-induced S and G2 arrest.
    SAR-020106 is capable of abrogating Etoposide-induced cell cycle arrest with an IC50 of 55 nM and 91 nM in HT29 and SW620 cells, respectively. SAR-020106 is relatively nontoxic with a GI50 of 0.48 μM in HT29 and 2 μM in SW620, resulting in an activity index of 8.7 and 22, respectively. SAR-020106 inhibits cytotoxic drug-induced autophosphorylation of CHK1 at S296 and blocks the phosphorylation of CDK1 at Y15 in a dose-dependent fashion.
  • 体内研究:
    SAR-020106 (40 mg/kg; i.p.; administered on days 0, 1, 7, 8, 14, and 15) in combination with Irinotecan potentiates the antitumor activity in SW620 xenografts Animal Model: Nude mice bearing SW620 xenograft tumors Dosage: 40 mg/kg Administration: I.p.; administered on days 0, 1, 7, 8, 14, and 15 Result: There was a clear decrease in tumor growth associated with the combination with tumors reaching 300% by 12.5 days.
  • 参考文献:
    1. Walton MI, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther. 2010;9(1):89-100.
    2. Reader JC, et al. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J Med Chem. 2011;54(24):8328-8342.
  • 溶解性: Soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.612 ml 13.06 ml 26.12 ml
    5 mM 0.522 ml 2.612 ml 5.224 ml
    10 mM 0.261 ml 1.306 ml 2.612 ml
    50 mM 0.052 ml 0.261 ml 0.522 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。